-
Je něco špatně v tomto záznamu ?
Specific pathogenic mutations in the M3 domain of the GluN1 subunit regulate the surface delivery and pharmacological sensitivity of NMDA receptors
M. Kolcheva, S. Kortus, BH. Krausova, P. Barackova, A. Misiachna, S. Danacikova, M. Kaniakova, K. Hemelikova, M. Hotovec, K. Rehakova, M. Horak
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- agonisté excitačních aminokyselin aplikace a dávkování MeSH
- antagonisté excitačních aminokyselin aplikace a dávkování MeSH
- HEK293 buňky MeSH
- hipokampus účinky léků fyziologie MeSH
- krysa rodu rattus MeSH
- kultivované buňky MeSH
- lidé MeSH
- mutace účinky léků genetika MeSH
- podjednotky proteinů agonisté antagonisté a inhibitory genetika MeSH
- potkani Wistar MeSH
- povrchové vlastnosti účinky léků MeSH
- proteiny nervové tkáně agonisté antagonisté a inhibitory genetika MeSH
- receptory N-methyl-D-aspartátu agonisté antagonisté a inhibitory genetika MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
N-methyl-d-aspartate receptors (NMDARs) play an essential role in regulating glutamatergic neurotransmission. Recently, pathogenic missense mutations were identified in genes encoding NMDAR subunits; however, their effect on NMDAR activity is often poorly understood. Here, we examined whether three previously identified pathogenic mutations (M641I, A645S, and Y647S) in the M3 domain of the GluN1 subunit affect the receptor's surface delivery, agonist sensitivity, Mg2+ block, and/or inhibition by the FDA-approved NMDAR blocker memantine. When expressed in HEK293 cells, we found reduced surface expression of GluN1-M641I/GluN2A, GluN1-Y647S/GluN2A, and GluN1-Y647S/GluN2B receptors; other mutation-bearing NMDAR combinations, including GluN1/GluN3A receptors, were expressed at normal surface levels. When expressed in rat hippocampal neurons, we consistently found reduced surface expression of the GluN1-M641I and GluN1-Y647S subunits when compared with wild-type GluN1 subunit. At the functional level, we found that GluN1-M641I/GluN2 and GluN1-A645S/GluN2 receptors expressed in HEK293 cells have wild-type EC50 values for both glutamate and glycine; in contrast, GluN1-Y647S/GluN2 receptors do not produce glutamate-induced currents. In the presence of a physiological concentration of Mg2+, we found that GluN1-M641I/GluN2 receptors have a lower memantine IC50 and slower offset kinetics, whereas GluN1-A645S/GluN2 receptors have a higher memantine IC50 and faster offset kinetics when compared to wild-type receptors. Finally, we found that memantine was the most neuroprotective in hippocampal neurons expressing GluN1-M641I subunits, followed by neurons expressing wild-type GluN1 and then GluN1-A645S subunits in an NMDA-induced excitotoxicity assay. These results indicate that specific pathogenic mutations in the M3 domain of the GluN1 subunit differentially affect the trafficking and functional properties of NMDARs.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004344
- 003
- CZ-PrNML
- 005
- 20220127145327.0
- 007
- ta
- 008
- 220113s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.neuropharm.2021.108528 $2 doi
- 035 __
- $a (PubMed)33773999
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kolcheva, Marharyta $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic; Department of Physiology, Faculty of Science, Charles University in Prague, Albertov 6, 12843, Prague 2, Czech Republic; Laboratory of Cellular Neurophysiology, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
- 245 10
- $a Specific pathogenic mutations in the M3 domain of the GluN1 subunit regulate the surface delivery and pharmacological sensitivity of NMDA receptors / $c M. Kolcheva, S. Kortus, BH. Krausova, P. Barackova, A. Misiachna, S. Danacikova, M. Kaniakova, K. Hemelikova, M. Hotovec, K. Rehakova, M. Horak
- 520 9_
- $a N-methyl-d-aspartate receptors (NMDARs) play an essential role in regulating glutamatergic neurotransmission. Recently, pathogenic missense mutations were identified in genes encoding NMDAR subunits; however, their effect on NMDAR activity is often poorly understood. Here, we examined whether three previously identified pathogenic mutations (M641I, A645S, and Y647S) in the M3 domain of the GluN1 subunit affect the receptor's surface delivery, agonist sensitivity, Mg2+ block, and/or inhibition by the FDA-approved NMDAR blocker memantine. When expressed in HEK293 cells, we found reduced surface expression of GluN1-M641I/GluN2A, GluN1-Y647S/GluN2A, and GluN1-Y647S/GluN2B receptors; other mutation-bearing NMDAR combinations, including GluN1/GluN3A receptors, were expressed at normal surface levels. When expressed in rat hippocampal neurons, we consistently found reduced surface expression of the GluN1-M641I and GluN1-Y647S subunits when compared with wild-type GluN1 subunit. At the functional level, we found that GluN1-M641I/GluN2 and GluN1-A645S/GluN2 receptors expressed in HEK293 cells have wild-type EC50 values for both glutamate and glycine; in contrast, GluN1-Y647S/GluN2 receptors do not produce glutamate-induced currents. In the presence of a physiological concentration of Mg2+, we found that GluN1-M641I/GluN2 receptors have a lower memantine IC50 and slower offset kinetics, whereas GluN1-A645S/GluN2 receptors have a higher memantine IC50 and faster offset kinetics when compared to wild-type receptors. Finally, we found that memantine was the most neuroprotective in hippocampal neurons expressing GluN1-M641I subunits, followed by neurons expressing wild-type GluN1 and then GluN1-A645S subunits in an NMDA-induced excitotoxicity assay. These results indicate that specific pathogenic mutations in the M3 domain of the GluN1 subunit differentially affect the trafficking and functional properties of NMDARs.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a agonisté excitačních aminokyselin $x aplikace a dávkování $7 D018690
- 650 _2
- $a antagonisté excitačních aminokyselin $x aplikace a dávkování $7 D018691
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a HEK293 buňky $7 D057809
- 650 _2
- $a hipokampus $x účinky léků $x fyziologie $7 D006624
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mutace $x účinky léků $x genetika $7 D009154
- 650 _2
- $a proteiny nervové tkáně $x agonisté $x antagonisté a inhibitory $x genetika $7 D009419
- 650 _2
- $a podjednotky proteinů $x agonisté $x antagonisté a inhibitory $x genetika $7 D021122
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a receptory N-methyl-D-aspartátu $x agonisté $x antagonisté a inhibitory $x genetika $7 D016194
- 650 _2
- $a povrchové vlastnosti $x účinky léků $7 D013499
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kortus, Stepan $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
- 700 1_
- $a Krausova, Barbora Hrcka $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
- 700 1_
- $a Barackova, Petra $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
- 700 1_
- $a Misiachna, Anna $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
- 700 1_
- $a Danacikova, Sarka $u Laboratory of Cellular Neurophysiology, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
- 700 1_
- $a Kaniakova, Martina $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
- 700 1_
- $a Hemelikova, Katarina $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
- 700 1_
- $a Hotovec, Matej $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
- 700 1_
- $a Rehakova, Kristyna $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic
- 700 1_
- $a Horak, Martin $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic. Electronic address: martin.horak@iem.cas.cz
- 773 0_
- $w MED00003497 $t Neuropharmacology $x 1873-7064 $g Roč. 189, č. - (2021), s. 108528
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33773999 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145324 $b ABA008
- 999 __
- $a ok $b bmc $g 1751719 $s 1155493
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 189 $c - $d 108528 $e 20210325 $i 1873-7064 $m Neuropharmacology $n Neuropharmacology $x MED00003497
- LZP __
- $a Pubmed-20220113